文献速递血管炎其他结缔组织病

抗TNF治疗预防DADA2患者缺血事件

Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2).
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该回顾性研究纳入31例基因确诊的DADA2患者,评估抗TNF治疗对血管炎性缺血事件的影响。结果显示抗TNF治疗显著降低中枢神经系统及非中枢神经系统缺血事件发生率(从每100患者月2.37次降至0.00次,P<0.0001),并显著降低儿童血管炎活动评分(PVAS),但对严重免疫缺陷或骨髓衰竭无效,后者需造血干细胞移植。

要点

  • 抗TNF治疗显著降低DADA2患者缺血事件发生率(P<0.0001)。
  • 抗TNF治疗显著降低PVAS评分,主要残留表现为轻度网状青斑皮疹。
  • 抗TNF对严重免疫缺陷或骨髓衰竭无效,需造血干细胞移植。

核心结论

  • 抗TNF治疗显著减少DADA2患者缺血事件和其他血管炎表现,但对免疫缺陷或骨髓衰竭无效。

研究设计与样本

  • 回顾性分析,纳入来自六个中心转诊至Great Ormond Street儿童医院的31例基因确诊DADA2患者。

主要发现

  • 抗TNF治疗前中枢神经系统和非中枢神经系统缺血事件中位发生率为每100患者月2.37次(IQR 1.25-3.63),治疗后为每100患者月0.00次(IQR 0.0-0.0),P<0.0001。
  • 抗TNF治疗前PVAS中位评分为20/63(IQR 13.0-25.8/63),治疗后为2/63(IQR 0.0-3.8/63),P<0.0001。
  • 抗TNF治疗对严重免疫缺陷或骨髓衰竭无效,这些患者需要造血干细胞移植。

关键数值与推荐

  • 31例患者中27例接受抗TNF治疗,中位治疗时间32个月(IQR 12.0-71.5个月)。
  • 抗TNF治疗前活动性疾病中位持续时间为73个月(IQR 27.5-133.5个月)。

临床怎么用

  • 对于DADA2患者,抗TNF治疗可用于减少缺血事件和血管炎表现,但需监测免疫缺陷和骨髓衰竭,必要时行造血干细胞移植。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the impact of anti-Tumour Necrosis Factor-α (anti-TNF) treatment on the occurrence of vasculitic ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). METHODS: A retrospective analysis of DADA2 patients referred from six centres to Great Ormond Street Hospital for Children was conducted. Ischaemic events, vasculitic disease activity, biochemical, immunological, and radiological features were compared, before and after anti-TNF treatment. RESULTS: A total of 31 patients with genetically confirmed DADA2 were included in the study. The median duration of active disease activity prior to anti-TNF treatment was 73 months (inter-quartile range [IQR] 27.5-133.5 months). Twenty seven/31 patients received anti-TNF treatment for a median of 32 months (IQR 12.0-71.5 months). The median event rate of central nervous system (CNS) and non-CNS ischemic events before anti-TNF treatment was 2.37 per 100 patient-months (IQR 1.25-3.63); compared with 0.00 per 100 patient-months (IQR 0.0-0.0) post-treatment (p< 0.0001). Paediatric vasculitis activity score (PVAS) was also significantly reduced: median score of 20/63 (IQR 13.0-25.8/63) pre-treatment vs. 2/63 (IQR 0.0-3.8/63) following anti-TNF treatment (p< 0.0001), with mild livedoid rash being the main persisting feature. Anti-TNF treatment was not effective for severe immunodeficiency or bone marrow failure, which required haematopoietic stem cell transplantation (HSCT). CONCLUSION: Anti-TNF treatment significantly reduced the incidence of ischaemic events and other vasculitic manifestations of DADA2, but was not effective for immunodeficiency or bone marrow failure.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Cooray S, Omyinmi E, Hong Y, et al. Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). Rheumatology (Oxford). 2021. PMID: 33420503. doi:10.1093/rheumatology/keaa837

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。